Why Is Arm Holdings Stock Trading Higher On Monday?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2024
0mins
Source: Benzinga
- ARM Stock Performance: ARM Holdings Plc stock is up after a sector selloff due to U.S. sanctions on the Middle East regarding AI chips.
- AI Readiness: CEO Rene Haas predicts 100 billion Arm devices globally ready for artificial intelligence by the end of 2025.
- Analysts' Projections: Analysts are optimistic about Arm Holdings, highlighting licensing interest, royalties, and potential in AI and datacenter markets.
- Future Plans: Arm Holdings plans to launch an AI chip in 2025 and commercialize it by fall 2025, with SoftBank eyeing investments in data centers powered by AI chips.
- Competition with AMD: Advanced Micro Devices hints at entering the next-generation AI PC market, setting up a potential rivalry with Arm.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMD
Wall Street analysts forecast AMD stock price to fall
33 Analyst Rating
25 Buy
8 Hold
0 Sell
Strong Buy
Current: 507.290
Low
210.00
Averages
289.13
High
377.00
Current: 507.290
Low
210.00
Averages
289.13
High
377.00
About AMD
Advanced Micro Devices, Inc. is a global semiconductor company. The Company is focused on high-performance computing and artificial intelligence (AI). Its segments include Data Center, Client and Gaming, and Embedded. Data Center segment includes AI accelerators, microprocessors (CPUs) for servers, graphics processing units (GPUs), accelerated processing units (APUs), data processing units (DPUs), Field Programmable Gate Arrays (FPGAs), and Adaptive system-on-Chip (SoC) products for data centers. Client and Gaming segment includes CPUs, APUs, chipsets for desktops and notebooks, discrete GPUs, and semi-custom SoC products and development services. Embedded segment includes embedded CPUs, APUs, FPGAs, system on modules (SOMs), and Adaptive SoC products. It markets and sells its products under the AMD trademark. Its products include AMD EPYC, AMD Ryzen, AMD Ryzen PRO, Virtex UltraScale+, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AMD Stock Soars with Promising AI Market Outlook
- Significant Revenue Growth: In Q1 2026, AMD reported $10.3 billion in revenue, a 38% year-over-year increase, with data center revenue reaching $5.8 billion, up 57%, highlighting strong demand and an enhanced market position in high-performance computing.
- Optimistic Future Outlook: Management guided for Q2 2026 revenue of approximately $11.2 billion, representing 46% year-over-year growth, with CEO Lisa Su noting that customer engagement around the new MI450 AI GPUs is strengthening, exceeding initial forecasts and indicating sustained market confidence in AMD's offerings.
- AI Market Share Expansion: The upcoming launch of MI450 AI chips has secured large-scale deployment commitments from major clients like OpenAI and Meta, further solidifying AMD's competitive position in the rapidly growing AI data center market, which is expected to drive future revenue growth.
- Valuation Reasonableness Analysis: Despite a 351% stock price increase over the past year, AMD's non-GAAP price-to-earnings-to-growth (PEG) ratio of 1.32 is below peers, suggesting the market remains cautious about its growth narrative, making recent pullbacks a potential buying opportunity for long-term investors.
See More
Three Stocks Thriving Amid Economic Headwinds
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine, mRNA-1010, aimed at addressing the low effectiveness of current flu vaccines, particularly for the elderly, which could significantly enhance its competitive position in the vaccine market.
- Krystal Biotech Strong Performance: Krystal Biotech has achieved positive earnings for 11 consecutive quarters with its gene therapy Vyjuvek, and as it expands into new markets in Europe, its revenue is expected to continue growing, showcasing its strong potential in the biotech sector.
- AMD Market Share Growth: AMD's stock has surged 129% year-to-date, with its desktop CPU market share rising to 33.2% and achieving a record 46.2% revenue share, indicating its strong competitive edge and pricing power in the AI sector.
- AI Market Opportunities: With the rise of agentic AI systems, AMD's EPYC processors are positioned as leaders in the server CPU market, potentially benefiting from a $200 billion market opportunity, further solidifying its industry standing.
See More
Investment Outlook for Moderna, Krystal Biotech, and AMD
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine mRNA-1010, which addresses a critical need for effective vaccines among the elderly, potentially enhancing the company's market position and financial performance significantly.
- Krystal Biotech Growth Potential: Krystal Biotech has achieved 11 consecutive quarters of earnings growth with its gene therapy Vyjuvek for a rare disease, and it still has a large addressable market to explore, with upcoming clinical data likely to further boost its stock price.
- AMD Market Leadership: AMD's stock has soared 129% year-to-date, and its leadership in the server CPU market positions it well to capitalize on the rapidly growing artificial intelligence sector, which is expected to continue driving revenue and market share growth.
- Economic and Market Performance: Despite economic and geopolitical challenges, the S&P 500 has risen 8% so far this year, demonstrating overall market resilience, with standout performances from companies like Moderna, Krystal Biotech, and AMD, making them attractive investment options.
See More
Three Stocks Outperforming the Market
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine mRNA-1010, which could significantly improve health outcomes for elderly patients and meet the urgent market need for effective vaccines, potentially leading to stronger financial performance over the next two years.
- Krystal Biotech Growth Momentum: Krystal Biotech has achieved positive earnings for 11 consecutive quarters with its gene therapy Vyjuvek for a rare disease, and it is expected to continue expanding its market presence while launching more clinical trial candidates, driving sustained revenue growth.
- AMD Market Leadership: AMD's stock has surged 129% year-to-date, with its desktop CPU market share reaching 33.2% and a record revenue share of 46.2%, showcasing its strong competitive position in the rapidly growing artificial intelligence sector.
- Optimistic Investment Outlook: Despite significant stock price increases for Moderna, Krystal Biotech, and AMD, they are still viewed as worthwhile investments, with potential for higher returns in the future, particularly against the backdrop of ongoing innovation and market expansion in their respective fields.
See More
Apple Partners with Intel for U.S. Chip Production
- Deal Announcement: President Trump revealed on social media that Apple has reached a preliminary agreement with Intel to collaboratively design and manufacture chips, marking a significant milestone after over a year of discussions.
- Manufacturing Diversification: This partnership will aid Apple in diversifying its manufacturing base, reducing reliance on TSMC, whose advanced production lines are in high demand from AI chipmakers like Nvidia and AMD.
- Increased Chip Capacity: By collaborating with Intel, Apple is expected to enhance its chip capacity to meet the growing market demand, particularly in the AI and high-performance computing sectors.
- Strengthened Market Position: This move not only bolsters Apple's competitiveness in chip manufacturing but also potentially provides stronger technical support for future product innovations, further solidifying its market position.
See More
RXT, NBIS, and ARM Shares Surge on Bullish Growth Outlook
- RXT Stock Surge: RXT shares soared over 21% on Wednesday to $8.60, driven by a bullish note from RBC Capital which raised its price target from $2.50 to $4, highlighting the AMD partnership as a key growth catalyst.
- NBIS Expansion Optimism: NBIS shares jumped to a 52-week high of $297.93, as investors rewarded its aggressive expansion in AI cloud infrastructure, with expectations of joining the Nasdaq 100 Index this month boosting market confidence.
- ARM Stock Hits New High: ARM shares climbed to $444.80, a 52-week high, after Bernstein raised its price target from $300 to $500, citing its growing role in powering agentic AI workloads, with a projected revenue of $22 billion by 2030.
- Surge in AI Market Demand: All three companies benefited from a surge in AI-related demand, with RXT's stock up 676% year-to-date and NBIS up 212%, reflecting strong market demand for AI infrastructure and investor optimism.
See More
AMD Stock Soars with Promising AI Market Outlook
- Significant Revenue Growth: In Q1 2026, AMD reported $10.3 billion in revenue, a 38% year-over-year increase, with data center revenue reaching $5.8 billion, up 57%, highlighting strong demand and an enhanced market position in high-performance computing.
- Optimistic Future Outlook: Management guided for Q2 2026 revenue of approximately $11.2 billion, representing 46% year-over-year growth, with CEO Lisa Su noting that customer engagement around the new MI450 AI GPUs is strengthening, exceeding initial forecasts and indicating sustained market confidence in AMD's offerings.
- AI Market Share Expansion: The upcoming launch of MI450 AI chips has secured large-scale deployment commitments from major clients like OpenAI and Meta, further solidifying AMD's competitive position in the rapidly growing AI data center market, which is expected to drive future revenue growth.
- Valuation Reasonableness Analysis: Despite a 351% stock price increase over the past year, AMD's non-GAAP price-to-earnings-to-growth (PEG) ratio of 1.32 is below peers, suggesting the market remains cautious about its growth narrative, making recent pullbacks a potential buying opportunity for long-term investors.
See More
Three Stocks Thriving Amid Economic Headwinds
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine, mRNA-1010, aimed at addressing the low effectiveness of current flu vaccines, particularly for the elderly, which could significantly enhance its competitive position in the vaccine market.
- Krystal Biotech Strong Performance: Krystal Biotech has achieved positive earnings for 11 consecutive quarters with its gene therapy Vyjuvek, and as it expands into new markets in Europe, its revenue is expected to continue growing, showcasing its strong potential in the biotech sector.
- AMD Market Share Growth: AMD's stock has surged 129% year-to-date, with its desktop CPU market share rising to 33.2% and achieving a record 46.2% revenue share, indicating its strong competitive edge and pricing power in the AI sector.
- AI Market Opportunities: With the rise of agentic AI systems, AMD's EPYC processors are positioned as leaders in the server CPU market, potentially benefiting from a $200 billion market opportunity, further solidifying its industry standing.
See More
Investment Outlook for Moderna, Krystal Biotech, and AMD
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine mRNA-1010, which addresses a critical need for effective vaccines among the elderly, potentially enhancing the company's market position and financial performance significantly.
- Krystal Biotech Growth Potential: Krystal Biotech has achieved 11 consecutive quarters of earnings growth with its gene therapy Vyjuvek for a rare disease, and it still has a large addressable market to explore, with upcoming clinical data likely to further boost its stock price.
- AMD Market Leadership: AMD's stock has soared 129% year-to-date, and its leadership in the server CPU market positions it well to capitalize on the rapidly growing artificial intelligence sector, which is expected to continue driving revenue and market share growth.
- Economic and Market Performance: Despite economic and geopolitical challenges, the S&P 500 has risen 8% so far this year, demonstrating overall market resilience, with standout performances from companies like Moderna, Krystal Biotech, and AMD, making them attractive investment options.
See More
Three Stocks Outperforming the Market
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine mRNA-1010, which could significantly improve health outcomes for elderly patients and meet the urgent market need for effective vaccines, potentially leading to stronger financial performance over the next two years.
- Krystal Biotech Growth Momentum: Krystal Biotech has achieved positive earnings for 11 consecutive quarters with its gene therapy Vyjuvek for a rare disease, and it is expected to continue expanding its market presence while launching more clinical trial candidates, driving sustained revenue growth.
- AMD Market Leadership: AMD's stock has surged 129% year-to-date, with its desktop CPU market share reaching 33.2% and a record revenue share of 46.2%, showcasing its strong competitive position in the rapidly growing artificial intelligence sector.
- Optimistic Investment Outlook: Despite significant stock price increases for Moderna, Krystal Biotech, and AMD, they are still viewed as worthwhile investments, with potential for higher returns in the future, particularly against the backdrop of ongoing innovation and market expansion in their respective fields.
See More
Apple Partners with Intel for U.S. Chip Production
- Deal Announcement: President Trump revealed on social media that Apple has reached a preliminary agreement with Intel to collaboratively design and manufacture chips, marking a significant milestone after over a year of discussions.
- Manufacturing Diversification: This partnership will aid Apple in diversifying its manufacturing base, reducing reliance on TSMC, whose advanced production lines are in high demand from AI chipmakers like Nvidia and AMD.
- Increased Chip Capacity: By collaborating with Intel, Apple is expected to enhance its chip capacity to meet the growing market demand, particularly in the AI and high-performance computing sectors.
- Strengthened Market Position: This move not only bolsters Apple's competitiveness in chip manufacturing but also potentially provides stronger technical support for future product innovations, further solidifying its market position.
See More
RXT, NBIS, and ARM Shares Surge on Bullish Growth Outlook
- RXT Stock Surge: RXT shares soared over 21% on Wednesday to $8.60, driven by a bullish note from RBC Capital which raised its price target from $2.50 to $4, highlighting the AMD partnership as a key growth catalyst.
- NBIS Expansion Optimism: NBIS shares jumped to a 52-week high of $297.93, as investors rewarded its aggressive expansion in AI cloud infrastructure, with expectations of joining the Nasdaq 100 Index this month boosting market confidence.
- ARM Stock Hits New High: ARM shares climbed to $444.80, a 52-week high, after Bernstein raised its price target from $300 to $500, citing its growing role in powering agentic AI workloads, with a projected revenue of $22 billion by 2030.
- Surge in AI Market Demand: All three companies benefited from a surge in AI-related demand, with RXT's stock up 676% year-to-date and NBIS up 212%, reflecting strong market demand for AI infrastructure and investor optimism.
See More
